The European health care market is not an easy one to navigate but insulin patch pump company Insulet Corp. is confident it will be able to tackle it on its own, following the decision to part ways with its exclusive European distributor of nearly eight years Ypsomed.
The two companies announced July 20 they will not be renewing their partnership, which started back in 2010, and that Insulet will take complete ownership of its Omnipod insulin patch...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?